Interstitial Lung Diseases Market

Interstitial Lung Diseases Market Size (2023 to 2028)

The global interstitial lung diseases market size is predicted to be worth USD 1594 million in 2023 and USD 2183 million by 2028, growing at a CAGR of 6.5% from 2023 to 2028.

MARKET DRIVERS:

The growing patient population suffering from interstitial lung diseases primarily propels the global market growth. Factors such as the increasing population of aged people in many countries, growing environmental pollution and an increase in the content of silica, dust, and asbestos are responsible for the diagnosis of many lung diseases among people. These factors are steadily driving the incidence of interstitial lung diseases and contributing to the global market growth. Autoimmune disorders such as scleroderma and rheumatoid arthritis are also the cause of interstitial lung diseases. The incidence of autoimmune disorders is becoming common among people these days due to the rapidly changing lifestyles and suppressed immune systems, which is resulting in the growing prevalence of interstitial lung diseases and fuelling the global interstitial lung diseases market growth.

The growing usage of personalized medicine for interstitial lung diseases contributes to the global market growth. Various types of interfacial lung diseases are present and each type of the disease can show different symptoms as per the climate of the region and the immune response of the personnel. So, personalized medicines can give the patient the most effective treatment in such cases.  

MARKET RESTRAINTS:

High costs associated with the treatment options of interstitial lung diseases are one of the key factors hampering the global market growth. The treatment cost for interstitial lung diseases is relatively expensive, which could restrict the treatment to a limited number of patients as patients with scarce financial resources could not afford the treatment for interstitial lung diseases. Lack of awareness regarding interstitial lung diseases among the public further hinders the global market growth. This lack of knowledge can affect the treatment and might also cause in delay in the diagnosis of the disease. The side effects associated with using drugs to treat interstitial lung diseases impede the global market growth. The drugs available in the market for the treatment of interstitial lung diseases have many side effects. For instance, Idiopathic Pulmonary fibrosis (IPF) Has no proper cure to date and the available drugs only slow down the spread of the disease. However, the drug has many side effects, like nausea, vomiting, and damage to the liver in many cases. There are many risks and complications associated with interstitial lung diseases including respiratory failure, heart failure and even death in some of the cases.

Impact of COVID-19 on the interstitial lung diseases market:

The COVID-19 pandemic had a positive impact on the growth of the interstitial lung diseases market. During the COVID-19 outbreak, most of the patients infected with the virus were also suffering from some or the other interstitial lung disease. During the COVID-19 pandemic, among the total patients being hospitalized, 20% of them were being hospitalized due to post-COVID-19 interstitial lung disease. (PC-ILD). A treatment method named Ofev has been approved by the US FDA during the COVID-19 pandemic. Its application along with the existing treatment methods can significantly lower the progression of interstitial lung diseases market all over the world.

REPORT COVERAGE:

This research report on the global interstitial lung diseases market has been segmented and sub-segmented based on the following categories.

Interstitial Lung Diseases Market - By Disease Type:

• Interstitial Pneumonia
• Nonspecific Interstitial Pneumonitis
• Idiopathic Pulmonary Fibrosis (IPF)

The idiopathic pulmonary fibrosis segment is expected to account for the largest share of the global market during the forecast period. IPF is an Irreversible lung disorder that causes lung tissue scarring. Due to the scarring of the lungs, the oxygen could not be pumped into the bloodstream, which leads to breathlessness and other related respiratory problems. To date, there is no treatment available for idiopathic pulmonary fibrosis.

The interstitial pneumonia segment held the second leading share of the worldwide market in 2022 and is predicted to capture a substantial share of the worldwide market during the forecast period. Inflammation of the lungs is scientifically termed interstitial pneumonia. It can occur due to various external as well as internal causative factors like environmental pollutants or toxins, hereditary or autoimmune diseases and infection during a specific climatic condition.

The nonspecific interstitial pneumonitis segment is anticipated to occupy a considerable share of the global market during the forecast period. The nonspecific interstitial pneumonitis is the least commonly occurring condition among the three. Nonspecific interstitial pneumonitis is a form of interstitial pneumonia however the specific cause is not known.

Interstitial Lung Diseases Market - By Drug Type:

• Corticosteroids
• Pirfenidone
• Nintedanib

Based on drug type, the corticosteroids segment is predicted to hold the leading share of the interstitial lung diseases market during the forecast period. Corticosteroids reduce inflammation and are used for the treatment of various diseases related to the lungs.

The pirfenidone segment is estimated to account for the second largest share of the worldwide market during the forecast period.  Pirfenidone is used to extend the progression of idiopathic pulmonary fibrosis (IPF), as it is an anti-fibrotic drug.

Interstitial Lung Diseases Market - By Region: 

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America is predicted to hold the largest share of the global interstitial lung diseases market during the forecast period. The presence of advanced healthcare infrastructure and the availability of technically advanced equipment for treatment drive the growth of the North American market. The prevalence of interstitial lung diseases is high in North America compared to all the other regions, which is further fuelling the growth of the North American market.

Europe was the second largest regional segment in the worldwide market in 2022 and is expected to grow at a healthy CAGR during the forecast period. The number of patients suffering from Idiopathic pulmonary fibrosis (IPF) is extensively increasing in the European region, which is primarily contributing to the growth of the European market. The cold climatic conditions throughout the year also increase the risk of interstitial lung diseases in the aged population.

The Asia Pacific region is predicted to witness a promising CAGR in the global market during the forecast period. Hairy environmental pollution in Asian countries like China, India, and Bangladesh is the major reason for a rising number of patients suffering from lung and other respiratory diseases.

KEY MARKET PLAYERS:

Liminal Biosciences, J.B Chemicals and Pharmaceuticals, Merck, Cipla, Glenmark Pharma, and F. Hoffmann-La Roche Ltd are some of the key market players.

RECENT DEVELOPMENTS IN THE MARKET:

• In March 2021, F. Hoffmann- La Roche Ltd. company’s, Actemra injection got approval from the US FDA.